Lilly(Eli) & Company
NYSE: LLY
$921.49
+$6.45 (+0.7%)
Closing Price on September 20, 2024
LLY Articles
Merrill Lynch reiterated a Buy rating and price objective on Eli Lilly after positive data on its Jardiance.
Published:
The gut-wrenching drop back in August, when the Dow opened down 1,000 points and the indexes went through the first 10% correction in almost four years was, needless to say, an eye-opener for...
Published:
Friday’s top analyst upgrades, downgrades and initiations include Aetna, Eli Lilly, Gilead Sciences, Royal Gold and Sirius XM.
Published:
Eli Lilly shares got a solid boost in the market Thursday morning as the broad markets were selling off.
Published:
With Panera Bread out of the Merrill Lynch US 1 List, these dividend contrarian plays could make good sense now.
Published:
ThinkstockWith a very nervous market, and the end of summer doldrums upon us, it may be time to look for ideas that will make sense when the market heats back up in the fall. One area that looks very...
Published:
24/7 Wall St. screened the Merrill Lynch health care universe and found four pharmaceutical stocks rated Buy with outstanding short-term and long-term potential.
Published:
Eli Lilly reported better-than-expected second-quarter earnings Thursday before the markets opened.
Published:
Earnings season is hitting its stride next week, and the health care sector, the biotech stocks in particular, have been on a roll for the past 12 months.
Published:
Last Updated:
Wednesday's top analyst upgrades, downgrades and initiations include Eli Lilly, Hertz, LinkedIn, NetApp, SINA, Vodafone and Wells Fargo.
Published:
A new report from Jefferies updates the firm's top global pharmaceutical stocks to buy, and these picks make sense for investors now.
Published:
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of July and added some color.
Published:
A new research report from Merrill Lynch features the catalyst-driven stocks ideas for the third quarter. These four had the largest upside to the posted target prices.
Published:
How much are big pharmaceutical companies really spending to get their drugs out there in the public eye?
Published:
When the American Society of Clinical Oncology (ASCO) decided to create a rating scale for cancer drugs, it certainly must have expected to get some pushback.
Published:
Last Updated: